US20090280179A1 - Resorbable Calcium Phosphate Based Biopolymer-Cross-Linked Bone Replacement Material - Google Patents
Resorbable Calcium Phosphate Based Biopolymer-Cross-Linked Bone Replacement Material Download PDFInfo
- Publication number
- US20090280179A1 US20090280179A1 US12/223,899 US22389907A US2009280179A1 US 20090280179 A1 US20090280179 A1 US 20090280179A1 US 22389907 A US22389907 A US 22389907A US 2009280179 A1 US2009280179 A1 US 2009280179A1
- Authority
- US
- United States
- Prior art keywords
- bone
- material according
- bone substituent
- substituent material
- cross
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 title claims abstract description 27
- 239000001506 calcium phosphate Substances 0.000 title claims abstract description 26
- 235000011010 calcium phosphates Nutrition 0.000 title claims abstract description 26
- 229910000389 calcium phosphate Inorganic materials 0.000 title claims abstract description 18
- 239000000316 bone substitute Substances 0.000 title abstract description 5
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 62
- 108010035532 Collagen Proteins 0.000 claims abstract description 26
- 102000008186 Collagen Human genes 0.000 claims abstract description 26
- 229920001436 collagen Polymers 0.000 claims abstract description 26
- 108010029541 Laccase Proteins 0.000 claims abstract description 21
- 239000002245 particle Substances 0.000 claims abstract description 10
- 239000011159 matrix material Substances 0.000 claims abstract description 9
- 125000002619 bicyclic group Chemical group 0.000 claims abstract description 8
- 125000003367 polycyclic group Chemical group 0.000 claims abstract description 8
- 125000002950 monocyclic group Chemical group 0.000 claims abstract description 5
- 239000000463 material Substances 0.000 claims description 41
- 125000001424 substituent group Chemical group 0.000 claims description 41
- 238000000465 moulding Methods 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000011368 organic material Substances 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 2
- 229910052681 coesite Inorganic materials 0.000 claims description 2
- 229910052906 cristobalite Inorganic materials 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 229910052682 stishovite Inorganic materials 0.000 claims description 2
- 229910052905 tridymite Inorganic materials 0.000 claims description 2
- 150000001491 aromatic compounds Chemical class 0.000 claims 8
- 229910052751 metal Inorganic materials 0.000 claims 3
- 239000002184 metal Substances 0.000 claims 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims 1
- 230000001788 irregular Effects 0.000 claims 1
- 239000010936 titanium Substances 0.000 claims 1
- 229910052719 titanium Inorganic materials 0.000 claims 1
- 238000004132 cross linking Methods 0.000 abstract description 25
- 230000007547 defect Effects 0.000 abstract description 17
- 239000000203 mixture Substances 0.000 abstract description 12
- 108010031396 Catechol oxidase Proteins 0.000 abstract description 9
- 102000030523 Catechol oxidase Human genes 0.000 abstract description 9
- 239000000853 adhesive Substances 0.000 abstract description 3
- 230000001070 adhesive effect Effects 0.000 abstract description 3
- 230000002479 lignolytic effect Effects 0.000 abstract description 3
- 229920000642 polymer Polymers 0.000 abstract description 3
- 239000000758 substrate Substances 0.000 abstract description 3
- 230000016446 peptide cross-linking Effects 0.000 abstract description 2
- 235000001014 amino acid Nutrition 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 239000004472 Lysine Substances 0.000 description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 11
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 8
- -1 sulfamindo Chemical group 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 7
- 108010038807 Oligopeptides Proteins 0.000 description 6
- 102000015636 Oligopeptides Human genes 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- YNCOLLPSNIHBGO-UHFFFAOYSA-N 2,5-dihydroxy-n-(2-hydroxyethyl)benzamide Chemical compound OCCNC(=O)C1=CC(O)=CC=C1O YNCOLLPSNIHBGO-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108010016626 Dipeptides Proteins 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000005245 sintering Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 0 [1*]C1=CC=C(C2=C(O)C=C([2*])C([3*])=C2)C=C1.[1*]C1=CC=C(C2=C([3*])C=C(O)C([2*])=C2)C=C1 Chemical compound [1*]C1=CC=C(C2=C(O)C=C([2*])C([3*])=C2)C=C1.[1*]C1=CC=C(C2=C([3*])C=C(O)C([2*])=C2)C=C1 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 239000012568 clinical material Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 238000003980 solgel method Methods 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011345 viscous material Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- FRXZIFVYTNMCHF-UHFFFAOYSA-N 2,5-dihydroxybenzamide Chemical class NC(=O)C1=CC(O)=CC=C1O FRXZIFVYTNMCHF-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001465180 Botrytis Species 0.000 description 1
- 241000222680 Collybia Species 0.000 description 1
- 241000222511 Coprinus Species 0.000 description 1
- 241000222356 Coriolus Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000123326 Fomes Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 241000222418 Lentinus Species 0.000 description 1
- MYTOTTSMVMWVJN-STQMWFEESA-N Lys-Tyr Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 MYTOTTSMVMWVJN-STQMWFEESA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000226677 Myceliophthora Species 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- RWCMHQZUYWBVAE-UHFFFAOYSA-N OS(=O)(=O)S(=O)(=O)S(O)(=O)=O Chemical group OS(=O)(=O)S(=O)(=O)S(O)(=O)=O RWCMHQZUYWBVAE-UHFFFAOYSA-N 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 241000222395 Phlebia Species 0.000 description 1
- 241000222350 Pleurotus Species 0.000 description 1
- 241000221945 Podospora Species 0.000 description 1
- 241000222640 Polyporus Species 0.000 description 1
- 241000222644 Pycnoporus <fungus> Species 0.000 description 1
- 241000231139 Pyricularia Species 0.000 description 1
- 241001361634 Rhizoctonia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000222354 Trametes Species 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910001576 calcium mineral Inorganic materials 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000009694 cold isostatic pressing Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000278 osteoconductive effect Effects 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920006389 polyphenyl polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J175/00—Adhesives based on polyureas or polyurethanes; Adhesives based on derivatives of such polymers
- C09J175/04—Polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/043—Mixtures of macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/08—Processes
- C08G18/10—Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/42—Polycondensates having carboxylic or carbonic ester groups in the main chain
- C08G18/4266—Polycondensates having carboxylic or carbonic ester groups in the main chain prepared from hydroxycarboxylic acids and/or lactones
- C08G18/428—Lactides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/64—Macromolecular compounds not provided for by groups C08G18/42 - C08G18/63
- C08G18/6415—Macromolecular compounds not provided for by groups C08G18/42 - C08G18/63 having nitrogen
- C08G18/6446—Proteins and derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L89/00—Compositions of proteins; Compositions of derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J189/00—Adhesives based on proteins; Adhesives based on derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Definitions
- the invention relates to a resorbable bone substituent material made of calcium phosphate particles of different phases which are embedded in a collagen matrix cross-linked being specific to the invention.
- Bone defects which cannot be closed in natural healing through the organism require the application of bone substituent materials which can be of natural or artificial origins, and which will fill the defect and be restructured to endogenous bone.
- the so-called “golden standard” represents the utilization of autologous bones then, i.e. the patient will be removed a piece of bone from the sound area, e.g. from the iliac crest (crista iliaca), which is used to fill the defect. Having greater bone defects or an inappropriate autologous bone, it is also fallen back upon foreign bone material which will be reconditioned accordingly.
- the advantage of providing foreign bones in larger quantities is confronted with their disadvantage that varying reconditioning processes may result in different mechanical properties (Palmer S. H., Gibbons C. L. M. H., Athanasou N. A.: JBJS (Br) 1999, 81-B, 333-5).
- the advantages of the synthetic bone substituents are in that checking the chemical composition and structure exists in addition to the availability, and influencing the biologically effective properties can be carried out such that an optimum course of therapy is achieved.
- the plurality of the synthetic bone substituents comprise calcium minerals such as calcium carbonate, calcium sulphate and different calcium phosphates.
- calcium phosphates such as ⁇ -tricalcium phosphate and hydroxylapatite have been used, wherein hydroxylapatite is an essential constituent of the natural bone (Dorozhkin S. V., Epple M.: Angew. Chemie 2002, 114, 3260-77).
- Calcium phosphate based bone substituent materials allow to be made in various embodiments for different ranges of application.
- Granulates are used for dental bone defect filling, e.g., whereas injectable cements are used with the stabilization of vertebral bodies.
- Load-carrying moulded ceramic articles are inserted with defects of the skull and the great long bones.
- mouldings are allowed to be generated both in immediately shaping processes (Michnaa S., Wua W., Lewis J. A.: Biomaterials 2005, 26, 5632-9), e.g. as a three-dimensional grid pattern, and produced by press forming (Weihe S., Wehmöller M., Tschakaloff A., von Oepen R., Schiller C., Epple M., Eufinger H.: Mund-, Kiefer-, typosgenic 2001, 5: 299-304).
- the porosity of these mouldings has to be set by the shaping process itself or by mechanical machining (D. Tadic D., M. Epple M.: Biomaterials 2003, 24, 4565-71).
- bone substituents which comprise adjustable components of calcium phosphates having different solubilities within the body fluid and thus various resorbence rates, the course of resorbence can be configured in a defined manner.
- the strain is additionally supported by the bone substituent material over a time period, in which new bone tissue is developing and solidifying.
- the calcium phosphates with less solubility will be completely reabsorbed later during remodelling of the bone (LeGeros R. Z.: Clinical Materials 1993, 14, 65-88).
- the problem formulation according to the invention is producing a positive non-brittle bone substitute moulding, i.e. being shaped anatomically and according to the defect, respectively, which completely fills the bone defect perfectly and which is resorbable as well.
- the solution of the problem formulation is achieved by producing the bone substituent from a mixture of calcium phosphate particles embedded into a collagen matrix being cross-linked according to the invention.
- collagen cross-linking is achieved by laccase-induced peptide cross-linking and suitable bridging molecules.
- the substituted dihydroxy aromatics and/or substrates of lygnolytical polyphenol oxidases such as laccases are generally suitable.
- monocyclic orthodihydroxy aromatics monocyclic paradihydroxy aromatics, bicyclic monohydro aromatics, polycyclic monohydroxy aromatics, bicyclic dihydroxy aromatics, polycyclic dihydroxy aromatics, bicyclic trihydroxy aromatics, polycyclic trihydroxy aromatics or mixtures thereof are used.
- the hydroxyl aromatics according to the invention are not part of a polymer chain.
- aromatics may be further substituted.
- Preferred functional groups are substituents selected from the group consisting of halogen, sulfo, sulfone, sulfamindo, sulfanyl, amino, amido, azo, imino and hydroxy.
- substituted aromatics in particular substituted dihydroxy aromatics, have very favourable polymerization properties such as fast polymerization, low natural linkage and good strength of cross-linking.
- Appropriate substitution of the aromatics results in that monohydroxy aromatics are also suitable as bridging molecule for cross-linking.
- substitution means that in addition to the hydroxyl groups 1, 2, 3 or 4 further groups are bonded to the aromatics.
- monohydroxylated biaryl compounds are also suited as bridging molecules.
- a bridging molecule Particularly preferred as a bridging molecule are phenol derivates which comprise a hydroxyl group or a methoxy group corresponding to the formulas 1 and 2, on the ortho position or para position,
- n 0-10, preferably 0 or 1, in particular 0; R 1 ⁇ OH or NH 2 or hal, preferably OH, Cl or Br, in particular OH; R 2 ⁇ H, CH 3 , CHO, COCH 3 , CONH 2 , CON-alkyl, CON-alkyl-OH, COOH, COO-alkyl, alkyl, substituted aromatic, in particular CON-alkyl or COO-alkyl, and R 3 ⁇ H, CH 3 , alkyl, substituted aromatic, in particular H or CH 3 .
- alkyl means branched or non-branched aliphatic hydrocarbon chains having preferably 1 to 20 carbon atoms, more preferably 1 to 6 carbons, e.g. methyl, ethyl propyl, butyl, isobutyl, n-pentyl, n-hexyl.
- Possible bridging molecules furthermore are compounds of formula 1 and of them the hydroquinone, which may be further substituted. Seen from a point of view of fast bonding reaction, if possible, substituted dihydroxy aromatics having a low natural linkage are particularly appropriate according to the invention. 2,5 dihydroxybenzamides are preferably used, wherein 2,5-dihydroxy-N-2-hydroxyethylbenzamide is particularly preferred.
- aromatic trihydroxy compounds it is preferred that there are not more than two hydroxyl groups per unit of benzene.
- Particularly preferred are polyphenyls, i.e. biphenyl or triphenyl of the following formula 3:
- n 0-10, preferably 0 or 1
- the phenyls of formula 3 may be substituted, e.g., in the ortho position into a hydroxyl group having CH 3 , CHO, COCH 3 , CONH 2 , CON-alkyl, CON-alkyl-OH, COOH, COO-alkyl, alkyl, substituted aromatic in particular CON-alkyl or COO-alkyl and/or in the metha position into a hydroxyl group having CH 3 , alkyl, substituted aromatic in particular CH 3 .
- Cross-linking of collagen occurs according to the invention under the influence of polyphenol oxidases such as lignolytic polyphenol oxidases, in particular laccases (EC 1.10.3.2).
- Laccases are known as cross-linkers. They are allowed to arise from plants, mushrooms, bacteria or insects or be derived from natural enzymes.
- the laccases to be used within the scope of this invention may be produced recombinantly or can be cleaned up.
- laccases being extracted from the species of aspergillus, neurospora, podospora, botrytis, collybia, fomes, lentinus, pleurotus, pycnoporus, pyricularia, trametes, rhizoctonia, coprinus, psatyrella, myceliophthora, schtalidium, polyporus, phlebia or coriolus .
- the preparation of laccases is disclosed in EP 0947142.
- the substrate spectrum thereof can be employed for the cross-linking reaction. Therefore, the invention particularly distinguishes in that a wide range of bridging molecules can be used for cross-linking.
- a preferred volume ratio for cross-linking of soft tissues is implemented in the formulation of 8.5 nM of collagen, 12.5 mM of 2,5-dihydroxy-N-2-hydroxyethylbenzamide, 0.32 U (156 nmol ml ⁇ 1 min ⁇ 1 ) of polyphenol oxidase.
- Cross-linking of a collagen matrix by means of bridging molecules with embedding calcium phosphate particles of different phases and concentrations into the matrix results in a solid material with the suitability as bone substituent.
- the polyphenol oxidase and the polyphenols are dissolved preferably in phosphate buffer such as calcium phosphate or sodium phosphate buffer or PBS.
- phosphate buffer such as calcium phosphate or sodium phosphate buffer or PBS.
- the consistency of the used components of laccase and polyphenol is from liquid to pasty.
- the viscosity of the used individual components can be varied by solvents.
- the concentration of the solvents influences cross-linking.
- Cross-linking reaction preferably occurs at pH value of 5 to 7.
- the reaction is allowed to proceed within the temperature range of 2 to 80 degrees centigrade, however, a temperature is preferred within the range of 20 to 37 degrees centigrade, in particular within the range of 25 to 30 degrees centigrade.
- another shorter-chain peptides can be used.
- about 50 percent of the amino acids of the peptide consist of lysine.
- Lysine and another amino acid may be arranged as a repeating dipeptide unit.
- Another succession or absorbing of further amino acids of, in particular arginine, asparagine, glutamine or histidine (instead of lysine or in addition thereto), serine or threonine (instead of tyrosine or in addition thereto), of cysteine or other amino acids is also possible.
- n can assume values of between 5 and 40 such as 5, 10 or 20.
- (lysine tyrosine) is advantageously used as a peptide.
- (lysine tyrosine) n within the matrix, lysine exists in a high concentration in the bone substituent material and has a positive effect on the proliferation and differentiation of bone cells.
- the substance mixture Prior to cross-linking, the substance mixture has viscous properties and can be arbitrarily shaped out. Then, simple shapes such as globules as well as complex mouldings can be represented.
- the material is configured as an interconnectingly porous body.
- the part by weight to the total weight of calcium phosphate particles is 70 to 95 percent, of collagen and oligopeptides is 5 to 15 percent if necessary, and of the bridging molecule substance is about 0.5 to 5 percent.
- the bone substituent materials according to the invention are allowed to include further substances.
- the material additionally includes SiO 2 .
- the bone substituent material can be doped with antibiotics. Then, antibiotics having free amino groups which have been mixed to the bone substituent prior to crosslinking will be bonded to collagen during the laccase-induced cross-linking. On that occasion, it could be demonstrated that the collagens doped in this manner with antibiotics have a strong antimicrobial effectiveness.
- the bone substituent material can be inserted with and without a supporting structure. If a resorbable organic material is inserted as supporting structure, it is of particular advantage according to the invention to select an organic material carrying free amino groups.
- cross-linking occurs by means of bridging molecules not only toward the collagen but toward the supporting structure as well such that a solid connection is obtained, however, which will be substituted by endogenic tissue during the healing process.
- the mechanism of resorbence can be in a hydrolytical or enzymatical manner.
- the peptides can be decomposed, and individual fragments can be taken away and be separated. Alternatively, the fragments or amino acids are also allowed to be incorporated into the regenerating tissue.
- the porosity of the calcium phosphate moulding is directed. Consequently, the mechanical properties of the resulting composite moulding are depending on the direction as well.
- a mixture from particles of different modifications of calcium phosphate and collagen is homogeneously mixed with 2,5 dihydroxy-N-2-hydroxyethylbenzamide such that a concentration of 12.5 mM is achieved.
- Cross-linking is initiated by adding of laccase having an activity of 0.32 U (156 mmol ml ⁇ 1 min ⁇ 1 ). After curing of the adhesive the mineral constituents together with the adhesive material form, depending on the solid matter components, a high viscous or solid material.
- an experimental arrangement such as in the first embodiment is selected, however, in addition to the collagen an oligopeptide (length of 2 to approx. 100 amino acids, preferably approx. 4 to appr. 20 amino acids) is added.
- modified and atypical amino acids, respectively, such as hydroxylisine can also be comprised in the oligopeptide.
- Lysine containing oligopeptides are preferably used, and it is of particular advantage when lysine is approximately 50 percent of the amino acids of the peptide. Additionally, approximately 50 percent of the amino acids of the peptide may be tyrosine. Lysine and tyrosine may be arranged, e.g. as a repeating dipeptide unit.
- the oligopeptides described in the second embodiment are received in PBS (phosphate buffered saline, 2.7 M NaCl 2 , 54 mM KCl, 87 mM Na 2 HPO 4 , 30 mM KH 2 PO 4 , pH 7.4) and laccase is added (Component 1). 2,5-dihydroxy-N-2-hydroxyethyl-benzamide is dissolved in PBS (Component 2). After combining both components, mixing with particles of different modifications of calcium phosphate and collagen is carried out. The quantity of solvent is selected minimally in order to achieve a solution of the components as concentrated as possible.
- the viscous mixture of particles of different modifications of calcium phosphate and collagen, if necessary, and of further oligopeptides according to the second embodiment 2,5-dihydroxy-N-2-hydroxyethyl benzamide and laccase, is inserted by means of capillary action, pressurizing or vacuum into the pores of an interconnectingly porous brittle moulding prior to sintering based on calcium phosphate, which after curing forms a solid composite moulding in compound with the CaP moulding.
- the interconnectingly porous moulding is formed such that the inner surface thereof is largely covered with collagen being locally determined, cross-linked.
- a composite moulding according to the third embodiment is prepared with the specific feature that a simply open or multiply open hollow body or a closed hollow body is created by means of a multilayer cross-linking of contacting surfaces. After the implantation the recovery of the bone defect occurs while maintaining dimensional stability.
- a bone substituent according to the first embodiment Preparation of a bone substituent according to the first embodiment with the specific feature that an amino group carrying antibiotic has been homogeneously distributed in the mixture before adding of laccase. After cross-linking with the laccase the collagen is doped with the antibiotic. Thus, a bone substituent is formed which is active ingredient loaded both inside and on the surface.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Materials For Medical Uses (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A resorbable bone replacement material made of calcium phosphate particles of different phases which are embedded in an inventive-specific cross-linked collagen matrix. The goal is to form a non-brittle, bone replacement moulded body having a positive fit, i.e. having a shape which is anatomic and/or corresponds to the defect, which perfectly fills the bone defect and can be resorbed thereby. Said goal is achieved by producing the bone replacement material made of a mixture of calcium phosphate particles which is embedded in an inventive cross-linked collagen matrix. In particular, the collagen cross-linking is achieved by a Laccase-induced peptide cross-linking and suitable bridge molecules. Essentially substituted dihydroxyarmotes and/or substrates of the lignolytic polyphenoloxidases, such as Laccases, are suitable as bridge molecules. Also, monocyclic ortho-dihydroxyaromates, monocyclic para-dihydroxyaromates, bicyclic monohydroxyaromates, polycyclic monohydroxyaromates, bicyclic dihydroxyaromates, polycyclic dihydroxyaromates, bicyclic trihydroxyaromates, polycyclic trihydroxyaromates, or mixtures thereof are used. The inventive hydroxyaromates are not part of a polymer chain as opposed to the known conchal adhesive.
Description
- The invention relates to a resorbable bone substituent material made of calcium phosphate particles of different phases which are embedded in a collagen matrix cross-linked being specific to the invention.
- Bone defects which cannot be closed in natural healing through the organism require the application of bone substituent materials which can be of natural or artificial origins, and which will fill the defect and be restructured to endogenous bone.
- The so-called “golden standard” represents the utilization of autologous bones then, i.e. the patient will be removed a piece of bone from the sound area, e.g. from the iliac crest (crista iliaca), which is used to fill the defect. Having greater bone defects or an inappropriate autologous bone, it is also fallen back upon foreign bone material which will be reconditioned accordingly. The advantage of providing foreign bones in larger quantities is confronted with their disadvantage that varying reconditioning processes may result in different mechanical properties (Palmer S. H., Gibbons C. L. M. H., Athanasou N. A.: JBJS (Br) 1999, 81-B, 333-5). Moreover, with foreign bones infections cannot be excluded (Boyce, T., Edwards J., Scarborough N.: Orthop. Clin. North Am. 1999, 30(4), 571-81). For the application of a debiologized animal bone, the same objections apply as for the application of foreign bones such that various synthetic bone substituents have been developed.
- The advantages of the synthetic bone substituents are in that checking the chemical composition and structure exists in addition to the availability, and influencing the biologically effective properties can be carried out such that an optimum course of therapy is achieved.
- The plurality of the synthetic bone substituents comprise calcium minerals such as calcium carbonate, calcium sulphate and different calcium phosphates. In the past, particularly calcium phosphates such as β-tricalcium phosphate and hydroxylapatite have been used, wherein hydroxylapatite is an essential constituent of the natural bone (Dorozhkin S. V., Epple M.: Angew. Chemie 2002, 114, 3260-77).
- Calcium phosphate based bone substituent materials allow to be made in various embodiments for different ranges of application. Granulates are used for dental bone defect filling, e.g., whereas injectable cements are used with the stabilization of vertebral bodies. Load-carrying moulded ceramic articles are inserted with defects of the skull and the great long bones.
- In the load-carrying case, particular difficulties arise for bone substituent materials made of calcium phosphates. The necessary structure is allowed to carry defined maximum forces only, and the naturally available brittleness of synthetic calcium phosphates has to be compensated by an adapted producing process. The increase of strength is achieved, e.g. by sintering. Disadvantageously, the sintered calcium phosphates are reabsorbed then substantially more slowly than it would correspond to the normal course of therapy (LeGeros R. Z.: Clinical Materials 1993, 14, 65-88). Moreover, with sintering loss of nanoporosity is notched up.
- Another possibility to increase the strength of calcium phosphate based bone substituent materials is compression by cold isostatic pressing. However, the porosity of these mouldings then gets largely lost such that, for compensating this effect, macroscopic structuring has to be provided by mechanical remachining, e.g. bores (Tadic D., Epple M.: Biomaterials 2003, 24, 4565-71).
- If the mechanical stressability does not play the important part, then calcium phosphate based bone substituents can be produced with further processes permitting a better adjustment of the porosity. If one confines to inorganic components as material constituents, then in particular sol-gel processes are just right to generate open-pored network structures (Brinker C J., Scherer G. W.: Sol-Gel Science: The Physics and Chemistry of Sol-Gel Processing, Academic Press, 1990).
- In addition, if organic components are used as binding agents, then mouldings are allowed to be generated both in immediately shaping processes (Michnaa S., Wua W., Lewis J. A.: Biomaterials 2005, 26, 5632-9), e.g. as a three-dimensional grid pattern, and produced by press forming (Weihe S., Wehmöller M., Tschakaloff A., von Oepen R., Schiller C., Epple M., Eufinger H.: Mund-, Kiefer-, Gesichtschirurgie 2001, 5: 299-304). The porosity of these mouldings has to be set by the shaping process itself or by mechanical machining (D. Tadic D., M. Epple M.: Biomaterials 2003, 24, 4565-71).
- Through the application of bone substituents which comprise adjustable components of calcium phosphates having different solubilities within the body fluid and thus various resorbence rates, the course of resorbence can be configured in a defined manner. As a result, the strain is additionally supported by the bone substituent material over a time period, in which new bone tissue is developing and solidifying. The calcium phosphates with less solubility will be completely reabsorbed later during remodelling of the bone (LeGeros R. Z.: Clinical Materials 1993, 14, 65-88).
- In summary, it is to be noted that calcium phosphate based bone substituent materials are successfully used for the treatment of simple defects. However, at the moment application with heavy defects is not carried out due to of material-related problems. These problems above all rest in that the actual processes are not able to meet substantial requirements on bone substituent material and defect filling material bodies formed from it, respectively:
- (1) on the one hand, to produce positive bone substitute mouldings, i.e. shaped anatomically and according to the defect, respectively, which completely fill the bone defect perfectly and non-positive as well, and
- (2) on the other hand, to implement an easily resorbable structure.
- Moreover, with the application of the actual manufacturing processes it is very difficult to fit into the bone substituent material additional organic or inorganic matters having strongly varying concentrations as well as to provide an improvement of the load-carrying properties by means of embedded, permanent and resorbable supporting structures, respectively.
- The problem formulation according to the invention is producing a positive non-brittle bone substitute moulding, i.e. being shaped anatomically and according to the defect, respectively, which completely fills the bone defect perfectly and which is resorbable as well.
- The solution of the problem formulation is achieved by producing the bone substituent from a mixture of calcium phosphate particles embedded into a collagen matrix being cross-linked according to the invention.
- In particular, collagen cross-linking is achieved by laccase-induced peptide cross-linking and suitable bridging molecules.
- As bridging molecules the substituted dihydroxy aromatics and/or substrates of lygnolytical polyphenol oxidases such as laccases are generally suitable.
- Therefore, monocyclic orthodihydroxy aromatics, monocyclic paradihydroxy aromatics, bicyclic monohydro aromatics, polycyclic monohydroxy aromatics, bicyclic dihydroxy aromatics, polycyclic dihydroxy aromatics, bicyclic trihydroxy aromatics, polycyclic trihydroxy aromatics or mixtures thereof are used. In contrast to the well-known mussel glues, the hydroxyl aromatics according to the invention are not part of a polymer chain.
- These aromatics may be further substituted. Preferred functional groups are substituents selected from the group consisting of halogen, sulfo, sulfone, sulfamindo, sulfanyl, amino, amido, azo, imino and hydroxy. Then, it is to ascertain that substituted aromatics, in particular substituted dihydroxy aromatics, have very favourable polymerization properties such as fast polymerization, low natural linkage and good strength of cross-linking. Appropriate substitution of the aromatics results in that monohydroxy aromatics are also suitable as bridging molecule for cross-linking. Within the scope of this invention, substitution means that in addition to the hydroxyl groups 1, 2, 3 or 4 further groups are bonded to the aromatics. Further, monohydroxylated biaryl compounds are also suited as bridging molecules.
- Particularly preferred as a bridging molecule are phenol derivates which comprise a hydroxyl group or a methoxy group corresponding to the formulas 1 and 2, on the ortho position or para position,
- wherein
- n=0-10, preferably 0 or 1, in particular 0;
R1═OH or NH2 or hal, preferably OH, Cl or Br, in particular OH;
R2═H, CH3, CHO, COCH3, CONH2, CON-alkyl, CON-alkyl-OH, COOH, COO-alkyl, alkyl, substituted aromatic, in particular CON-alkyl or COO-alkyl, and
R3═H, CH3, alkyl, substituted aromatic, in particular H or CH3. - Herein, alkyl means branched or non-branched aliphatic hydrocarbon chains having preferably 1 to 20 carbon atoms, more preferably 1 to 6 carbons, e.g. methyl, ethyl propyl, butyl, isobutyl, n-pentyl, n-hexyl.
- Possible bridging molecules furthermore are compounds of formula 1 and of them the hydroquinone, which may be further substituted. Seen from a point of view of fast bonding reaction, if possible, substituted dihydroxy aromatics having a low natural linkage are particularly appropriate according to the invention. 2,5 dihydroxybenzamides are preferably used, wherein 2,5-dihydroxy-N-2-hydroxyethylbenzamide is particularly preferred.
- In the case of aromatic trihydroxy compounds it is preferred that there are not more than two hydroxyl groups per unit of benzene. Particularly preferred are polyphenyls, i.e. biphenyl or triphenyl of the following formula 3:
- wherein
- n=0-10, preferably 0 or 1,
and - Then, the phenyls of formula 3 may be substituted, e.g., in the ortho position into a hydroxyl group having CH3, CHO, COCH3, CONH2, CON-alkyl, CON-alkyl-OH, COOH, COO-alkyl, alkyl, substituted aromatic in particular CON-alkyl or COO-alkyl and/or in the metha position into a hydroxyl group having CH3, alkyl, substituted aromatic in particular CH3.
- Cross-linking of collagen occurs according to the invention under the influence of polyphenol oxidases such as lignolytic polyphenol oxidases, in particular laccases (EC 1.10.3.2). Laccases are known as cross-linkers. They are allowed to arise from plants, mushrooms, bacteria or insects or be derived from natural enzymes. The laccases to be used within the scope of this invention may be produced recombinantly or can be cleaned up.
- Examples thereof are laccases being extracted from the species of aspergillus, neurospora, podospora, botrytis, collybia, fomes, lentinus, pleurotus, pycnoporus, pyricularia, trametes, rhizoctonia, coprinus, psatyrella, myceliophthora, schtalidium, polyporus, phlebia or coriolus. The preparation of laccases is disclosed in EP 0947142.
- By the application of polyphenol oxidases such as lignolytic polyphenol oxidases, preferably laccase (EC 1.10.3.2), the substrate spectrum thereof can be employed for the cross-linking reaction. Therefore, the invention particularly distinguishes in that a wide range of bridging molecules can be used for cross-linking.
- Variations of the concentrations approximately of 1 to 50 mM are possible both with the individual component collagen and the bridging molecule matter.
- Then, it must be considered, that according to the selected bridging molecule, an interfering natural reaction of the bridging molecule takes place decreasing the formation of cross-linking bonds. An excessively low concentration of the bridging molecules results in a too slow reaction, an excessively high concentration results in stronger side reactions through natural linkage. The concentration of the polyphenol oxidase influences the reaction rate wherein, according to application, faster cross-linking or a longer processability of the combination can be achieved by varying the concentration. A preferred volume ratio for cross-linking of soft tissues, for example, is implemented in the formulation of 8.5 nM of collagen, 12.5 mM of 2,5-dihydroxy-N-2-hydroxyethylbenzamide, 0.32 U (156 nmol ml−1 min−1) of polyphenol oxidase.
- Cross-linking of a collagen matrix by means of bridging molecules with embedding calcium phosphate particles of different phases and concentrations into the matrix results in a solid material with the suitability as bone substituent.
- The polyphenol oxidase and the polyphenols are dissolved preferably in phosphate buffer such as calcium phosphate or sodium phosphate buffer or PBS. The consistency of the used components of laccase and polyphenol is from liquid to pasty. The viscosity of the used individual components can be varied by solvents. The concentration of the solvents influences cross-linking.
- Cross-linking reaction preferably occurs at pH value of 5 to 7. The reaction is allowed to proceed within the temperature range of 2 to 80 degrees centigrade, however, a temperature is preferred within the range of 20 to 37 degrees centigrade, in particular within the range of 25 to 30 degrees centigrade.
- In support of cross-linking another shorter-chain peptides can be used. In a particularly preferred embodiment of the invention about 50 percent of the amino acids of the peptide consist of lysine. Lysine and another amino acid may be arranged as a repeating dipeptide unit. Another succession or absorbing of further amino acids of, in particular arginine, asparagine, glutamine or histidine (instead of lysine or in addition thereto), serine or threonine (instead of tyrosine or in addition thereto), of cysteine or other amino acids is also possible.
- In a likewise preferred embodiment it exclusively concerns with polymers consisting of two amino acids such as (lysine tyrosine)n, wherein n can assume values of between 5 and 40 such as 5, 10 or 20.
- Furthermore, (lysine tyrosine), is advantageously used as a peptide. With the use of (lysine tyrosine)n within the matrix, lysine exists in a high concentration in the bone substituent material and has a positive effect on the proliferation and differentiation of bone cells.
- Prior to cross-linking, the substance mixture has viscous properties and can be arbitrarily shaped out. Then, simple shapes such as globules as well as complex mouldings can be represented.
- Furthermore, filling the porous mouldings with the viscous material and curing thereof is possible.
- In one preferred embodiment the material is configured as an interconnectingly porous body.
- Preferably, the part by weight to the total weight of calcium phosphate particles is 70 to 95 percent, of collagen and oligopeptides is 5 to 15 percent if necessary, and of the bridging molecule substance is about 0.5 to 5 percent.
- The bone substituent materials according to the invention are allowed to include further substances. In a preferred mode of implementation the material additionally includes SiO2.
- The bone substituent material can be doped with antibiotics. Then, antibiotics having free amino groups which have been mixed to the bone substituent prior to crosslinking will be bonded to collagen during the laccase-induced cross-linking. On that occasion, it could be demonstrated that the collagens doped in this manner with antibiotics have a strong antimicrobial effectiveness.
- The bone substituent material can be inserted with and without a supporting structure. If a resorbable organic material is inserted as supporting structure, it is of particular advantage according to the invention to select an organic material carrying free amino groups. In this case, cross-linking occurs by means of bridging molecules not only toward the collagen but toward the supporting structure as well such that a solid connection is obtained, however, which will be substituted by endogenic tissue during the healing process. The mechanism of resorbence can be in a hydrolytical or enzymatical manner. In particular, the peptides can be decomposed, and individual fragments can be taken away and be separated. Alternatively, the fragments or amino acids are also allowed to be incorporated into the regenerating tissue.
- In a further embodiment, the porosity of the calcium phosphate moulding is directed. Consequently, the mechanical properties of the resulting composite moulding are depending on the direction as well.
- By cross-linking the contacting surfaces of two mouldings having directionally depending mechanical properties which result in a solid connection of the mouldings, the directional dependence of the mechanical properties of the resulting moulding will be reduced.
- By means of the solid combination of a plurality of two-dimensional mouldings through cross-linking of their paired contacting surfaces, a multi-layer composite moulding is made which has a high mechanical stressability.
- A mixture from particles of different modifications of calcium phosphate and collagen is homogeneously mixed with 2,5 dihydroxy-N-2-hydroxyethylbenzamide such that a concentration of 12.5 mM is achieved. Cross-linking is initiated by adding of laccase having an activity of 0.32 U (156 mmol ml−1 min−1). After curing of the adhesive the mineral constituents together with the adhesive material form, depending on the solid matter components, a high viscous or solid material.
- An experimental arrangement such as in the first embodiment is selected, however, in addition to the collagen an oligopeptide (length of 2 to approx. 100 amino acids, preferably approx. 4 to appr. 20 amino acids) is added. Compared with usual proteinaceous amino acids, modified and atypical amino acids, respectively, such as hydroxylisine can also be comprised in the oligopeptide. Lysine containing oligopeptides are preferably used, and it is of particular advantage when lysine is approximately 50 percent of the amino acids of the peptide. Additionally, approximately 50 percent of the amino acids of the peptide may be tyrosine. Lysine and tyrosine may be arranged, e.g. as a repeating dipeptide unit. In particular, by adding peptides which consisted of repeating dipeptide units of lysine and tyrosine ([lys-tyr]n or [tyr˜lys]n, n=5 or n=10, good cross-linking has been achieved with the incorporation of the collagen and inclusion of the calcium phosphates.
- The oligopeptides described in the second embodiment are received in PBS (phosphate buffered saline, 2.7 M NaCl2, 54 mM KCl, 87 mM Na2HPO4, 30 mM KH2PO4, pH 7.4) and laccase is added (Component 1). 2,5-dihydroxy-N-2-hydroxyethyl-benzamide is dissolved in PBS (Component 2). After combining both components, mixing with particles of different modifications of calcium phosphate and collagen is carried out. The quantity of solvent is selected minimally in order to achieve a solution of the components as concentrated as possible.
- The viscous mixture of particles of different modifications of calcium phosphate and collagen, if necessary, and of further oligopeptides according to the second embodiment 2,5-dihydroxy-N-2-hydroxyethyl benzamide and laccase, is inserted by means of capillary action, pressurizing or vacuum into the pores of an interconnectingly porous brittle moulding prior to sintering based on calcium phosphate, which after curing forms a solid composite moulding in compound with the CaP moulding. In a specific embodiment, the interconnectingly porous moulding is formed such that the inner surface thereof is largely covered with collagen being locally determined, cross-linked.
- After cross-linking initiated by laccase, a material being interconnectingly porous with regard to both the mineral and the collagen is obtained. When implanted, due to its osteoconductive action this material serves as a biological guide bar for the regeneration of missing bone and thus for healing the defect.
- A composite moulding according to the third embodiment is prepared with the specific feature that a simply open or multiply open hollow body or a closed hollow body is created by means of a multilayer cross-linking of contacting surfaces. After the implantation the recovery of the bone defect occurs while maintaining dimensional stability.
- Preparation of a bone substituent according to the first embodiment with the specific feature that an amino group carrying antibiotic has been homogeneously distributed in the mixture before adding of laccase. After cross-linking with the laccase the collagen is doped with the antibiotic. Thus, a bone substituent is formed which is active ingredient loaded both inside and on the surface.
- Preparation of a multilayer composite moulding according to the sixth embodiment with the specific feature that identical or different active ingredients will be embedded into one or several layer boundaries.
Claims (16)
1. A resorbable bone substituent material comprising calcium phosphate particles of different phases and collagen, wherein the collagen is in the form of a matrix that is at least partially cross-linked by a substituted polyhydroxy aromatic compound under the action of a laccase.
2. A resorbable bone substituent material according to claim 1 , wherein the substituted polyhydroxy aromatic compound is selected from the group consisting of: monocyclic dihydroxy aromatic compounds, bicyclic dihydroxy aromatic compounds, polycyclic dihydroxy aromatic compounds, bicyclic trihydroxy aromatic compounds, and polycyclic trihydroxy aromatic compounds.
3. A resorbable bone substituent material according to claim 2 , wherein the substituted polyhydroxy aromatic compound has a molecular weight of 110 to 1100 g/mol.
4. A resorbable bone substituent material according to claim 3 , wherein the polyhydroxy aromatic is 2,5-dihydroxy-N-2-hydroxyethyl benzamide.
5. A bone substituent material according to claim 1 , the bone substituent material being in the form of an interconnectingly porous body.
6. A bone substituent material according to claim 1 , wherein the collagen matrix additionally comprises a SiO2 gel.
7. A bone substituent material according to claim 5 , wherein the interconnectingly porous body has an inner surface and is formed such that the majority of the inner surface thereof is largely covered by crosslinked collagen which is locally determined.
8. A bone substituent material according to claim 1 , wherein the various material components are arranged in an irregular sequence or regular sequence.
9. A bone substituent material according to claim 1 in the form of a moulding.
10. A bone substituent material according to claim 9 , further comprising an internal supporting structure.
11. A bone substituent material according to claim 10 , wherein the supporting structure consists of a metal.
12. A bone substituent material according to claim 11 , wherein the metal is resorbable.
13. A bone substituent material according to claim 10 , wherein the internal supporting structure consists of resorbable organic material.
14. A bone substituent material according to claim 1 further comprising one or more active ingredients on either or both of external and internal surfaces.
15. A bone substituent material according to claim 11 , characterized in that said active ingredients will be introduced into the volume and will be just released through the resorbance of the material.
16. A bone substituent material according to claim 11 , wherein said metal comprises titanium.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006006904A DE102006006904A1 (en) | 2006-02-09 | 2006-02-09 | New haemostatic agents and adhesives for medical applications |
| DE102006006904.8 | 2006-02-09 | ||
| PCT/EP2007/051251 WO2007090880A2 (en) | 2006-02-09 | 2007-02-09 | Reabsorabable calcium phosphate based biopolymer-cross-linked bone replacement material |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20090280179A1 true US20090280179A1 (en) | 2009-11-12 |
Family
ID=38261578
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/223,772 Active US7923003B2 (en) | 2006-02-09 | 2007-02-09 | Adhesive for medical applications and means for haemostasis |
| US12/223,899 Abandoned US20090280179A1 (en) | 2006-02-09 | 2007-02-09 | Resorbable Calcium Phosphate Based Biopolymer-Cross-Linked Bone Replacement Material |
| US13/037,850 Expired - Fee Related US8440209B2 (en) | 2006-02-09 | 2011-03-01 | Adhesive for medical applications and means for haemostasis |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/223,772 Active US7923003B2 (en) | 2006-02-09 | 2007-02-09 | Adhesive for medical applications and means for haemostasis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/037,850 Expired - Fee Related US8440209B2 (en) | 2006-02-09 | 2011-03-01 | Adhesive for medical applications and means for haemostasis |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7923003B2 (en) |
| EP (5) | EP1984032B1 (en) |
| JP (2) | JP2009525799A (en) |
| CN (2) | CN101384284B (en) |
| AT (1) | ATE504317T1 (en) |
| AU (2) | AU2007213923C1 (en) |
| CA (2) | CA2637794C (en) |
| DE (2) | DE102006006904A1 (en) |
| ES (2) | ES2771824T3 (en) |
| WO (4) | WO2007090373A2 (en) |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7815926B2 (en) | 2005-07-11 | 2010-10-19 | Musculoskeletal Transplant Foundation | Implant for articular cartilage repair |
| US7837740B2 (en) | 2007-01-24 | 2010-11-23 | Musculoskeletal Transplant Foundation | Two piece cancellous construct for cartilage repair |
| US20110027381A1 (en) * | 2006-10-16 | 2011-02-03 | Universitat Rostock | Treatment of osteoporosis |
| US20110040323A1 (en) * | 2007-08-03 | 2011-02-17 | Aesculap Ag | Combination for an adhesive bonding of biological tissues |
| USRE42208E1 (en) | 2003-04-29 | 2011-03-08 | Musculoskeletal Transplant Foundation | Glue for cartilage repair |
| US7901457B2 (en) | 2003-05-16 | 2011-03-08 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
| US20110182965A1 (en) * | 2010-01-26 | 2011-07-28 | Warsaw Orthopedic, Inc. | Highly compression resistant matrix with porous skeleton |
| US20110243913A1 (en) * | 2010-04-06 | 2011-10-06 | Orthovita, Inc. | Biomaterial Compositions and Methods of Use |
| US8292968B2 (en) | 2004-10-12 | 2012-10-23 | Musculoskeletal Transplant Foundation | Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles |
| WO2012178031A1 (en) | 2011-06-23 | 2012-12-27 | Stryker Corporation | Prosthetic implant and method of implantation |
| US8435551B2 (en) | 2007-03-06 | 2013-05-07 | Musculoskeletal Transplant Foundation | Cancellous construct with support ring for repair of osteochondral defects |
| US9427334B2 (en) | 2013-03-08 | 2016-08-30 | Stryker Corporation | Bone pads |
| US9701940B2 (en) | 2005-09-19 | 2017-07-11 | Histogenics Corporation | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof |
| US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
| WO2018209101A1 (en) * | 2017-05-10 | 2018-11-15 | Marquette University | Medical and dental integrated multiphasic biomaterials for single or multi-tissue reconstruction/regeneration |
| US10182973B2 (en) | 2010-11-10 | 2019-01-22 | Stryker European Holdings I, Llc | Polymeric bone foam composition and method |
| US12268609B2 (en) | 2013-03-07 | 2025-04-08 | Howmedica Osteonics Corp. | Method of manufacturing a tibial implant |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007045066A1 (en) * | 2007-09-20 | 2009-04-02 | Mike Ehrlich | Hemostatic material containing synthetic peptides or polysaccharides |
| JP5545985B2 (en) * | 2010-06-03 | 2014-07-09 | コニシ株式会社 | Polylactic acid adhesive and method for producing the same |
| CN104144984A (en) | 2011-08-24 | 2014-11-12 | 阿尔吉斯有限责任公司 | Macrophyte-based bioplastic |
| US8791219B2 (en) | 2012-03-23 | 2014-07-29 | California Institute Of Technology | Rapidly crosslinkable adhesives for biomedical applications |
| DE102012107535A1 (en) | 2012-08-16 | 2014-02-20 | Bess Pro Gmbh | Bioresorbable adhesives and their use in the medical field |
| US10428254B2 (en) | 2014-01-08 | 2019-10-01 | Cambond Limited | Bio-adhesives |
| WO2017003872A1 (en) * | 2015-07-01 | 2017-01-05 | H.B. Fuller Company | Adhesive composition based on polylactide polyols |
| EP3231420A1 (en) * | 2016-02-29 | 2017-10-18 | G.L. Pharma GmbH | Abuse-deterrent pharmaceutical compositions |
| AR108339A1 (en) * | 2016-04-27 | 2018-08-08 | Cryovac Inc | MOVIE THAT HAS AN OXYGEN CLEANER AND A VOLATILE ORGANOLEPTIC COMPOUND CLEANER |
| US11998654B2 (en) | 2018-07-12 | 2024-06-04 | Bard Shannon Limited | Securing implants and medical devices |
| DE102018126394B4 (en) | 2018-10-23 | 2020-12-24 | Universität Rostock | Depot system containing probiotics for dental applications |
| CN109593736A (en) * | 2018-12-19 | 2019-04-09 | 江苏德和生物科技有限公司 | A kind of theaflavin production industrial production process of immobile polyphenol oxidase |
| CN110624136B (en) * | 2019-10-08 | 2021-12-17 | 威高集团有限公司 | Degradable medical composite material and preparation method and application thereof |
| CN111205817A (en) * | 2020-01-08 | 2020-05-29 | 山西大学 | Non-aldolase modified sugar-soybean-based composite wood adhesive and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5015677A (en) * | 1986-04-25 | 1991-05-14 | Bio-Polymers, Inc. | Adhesives derived from bioadhesive polyphenolic proteins |
| US20040037906A1 (en) * | 2002-05-13 | 2004-02-26 | State Of Oregon Acting By And Through The Oregon State | Modified protein adhesives and lignocellulosic composites made from the adhesives |
| US20050226904A1 (en) * | 2002-03-15 | 2005-10-13 | Hoon Choi | Fibrous composite for tissue engineering |
| US20050283255A1 (en) * | 2001-06-04 | 2005-12-22 | Perry Geremakis | Tissue-derived mesh for orthopedic regeneration |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5831901B2 (en) * | 1979-05-10 | 1983-07-09 | 忠敬 駒木根 | Inorganic antibacterial and antiseptic feed additives |
| DE3132379A1 (en) * | 1981-08-17 | 1983-02-24 | Degussa Ag, 6000 Frankfurt | ZEOLITE GRANULES, METHOD FOR THE PRODUCTION AND USE THEREOF |
| IT1157273B (en) * | 1982-05-07 | 1987-02-11 | Anic Spa | THERMOPLASTIC COMPOSITIONS BASED ON NON-POLAR ORGANIC POLYMERS AND ZEOLITES IN ACID FORM, WITH TENACE ADHESION TO METALS AND COMPOSITE OBJECTS OBTAINABLE THROUGH THE SAME |
| US4822349A (en) * | 1984-04-25 | 1989-04-18 | Hursey Francis X | Method of treating wounds |
| ES2025572T3 (en) * | 1986-04-25 | 1992-04-01 | Bio-Polymers, Inc. | PROCEDURE FOR MANUFACTURING ADHESIVES DERIVED FROM BIOADHESIVE POLYPHENOLIC PROTEINS. |
| US5140949A (en) * | 1989-09-19 | 1992-08-25 | Mobil Oil Corporation | Zeolite-clay composition and uses thereof |
| JPH0479845A (en) * | 1990-07-20 | 1992-03-13 | Hitachi Kako Kk | Granular additive for feed |
| JPH05337151A (en) * | 1992-06-11 | 1993-12-21 | Terumo Corp | Wound cover material |
| WO1994028937A1 (en) * | 1993-06-16 | 1994-12-22 | Enzon, Inc. | Conjugated biodhesives |
| US5583114A (en) * | 1994-07-27 | 1996-12-10 | Minnesota Mining And Manufacturing Company | Adhesive sealant composition |
| US5494744A (en) * | 1994-10-12 | 1996-02-27 | Kimberly-Clark Corporation | Method of applying a protein coating to a substrate and article thereof |
| GB9523581D0 (en) * | 1995-11-17 | 1996-01-17 | British Textile Tech | Cross-linking |
| JPH1045608A (en) * | 1996-04-17 | 1998-02-17 | Toya Seishi Kk | Zeolite-containing therapeutic agent for wound |
| GB2326827B (en) * | 1997-06-30 | 2002-02-20 | Johnson & Johnson Medical | Use of molecular sieves to promote wound healing |
| US6458095B1 (en) | 1997-10-22 | 2002-10-01 | 3M Innovative Properties Company | Dispenser for an adhesive tissue sealant having a housing with multiple cavities |
| DE69936982T2 (en) | 1998-03-06 | 2008-05-15 | Baxter International Inc., Deerfield | TURBULENCE MIXING HEAD FOR TISSUE ADHESIVE APPLICATOR AND SPRAYING HEAD FOR SAME |
| US6884230B1 (en) * | 1998-03-09 | 2005-04-26 | Baxter International Inc. | Dispensing head for a tissue sealant applicator and process of use |
| JP4137224B2 (en) * | 1998-03-31 | 2008-08-20 | 天野エンザイム株式会社 | Protein cross-linking method |
| GB2336156B (en) * | 1998-04-09 | 2003-05-07 | Mars Uk Ltd | Adhesives |
| DE69941498D1 (en) | 1998-11-12 | 2009-11-12 | Internat Mfg Group Inc | Hemostatic cross-linked dextran beads useful for rapid blood clotting and hemostasis |
| DE19958526A1 (en) * | 1998-12-17 | 2000-06-21 | Henkel Kgaa | Polyurethane adhesive useful especially for laminating applications is derived from polyisocyanate component and polyester-polyol component based on hydroxy-carboxylic acids, especially lactic acid |
| JP2002543930A (en) | 1999-05-12 | 2002-12-24 | デー アンド イー クライオー シーシー | Ceramic wound treatment device |
| EP1169922A1 (en) * | 2000-07-03 | 2002-01-09 | Instituut Voor Agrotechnologisch Onderzoek (Ato-Dlo) | Method of enzymatically cross-linking proteins and phenolic polymers |
| US20020114795A1 (en) | 2000-12-22 | 2002-08-22 | Thorne Kevin J. | Composition and process for bone growth and repair |
| DE10100404A1 (en) | 2001-01-05 | 2002-07-11 | Bayer Ag | Process for the production of polycarbonate |
| US20030087338A1 (en) * | 2001-07-20 | 2003-05-08 | Messersmith Phillip B. | Adhesive DOPA-containing polymers and related methods of use |
| DE10152407A1 (en) * | 2001-10-24 | 2003-05-08 | Aesculap Ag & Co Kg | Composition of at least two biocompatible chemically crosslinkable components |
| WO2003072118A1 (en) * | 2002-02-28 | 2003-09-04 | Gerold Lukowski | Micro/nanoparticle obtained from lipid-containing marine organisms for use in pharmaceutics and cosmetics |
| JP2003305117A (en) * | 2002-04-18 | 2003-10-28 | Toya Seishi Kk | Tourmaline filled tube |
| JP4120832B2 (en) * | 2002-06-17 | 2008-07-16 | 日本電気株式会社 | Biodegradable resin, biodegradable resin composition, biodegradable molded article, and method for producing biodegradable resin |
| DE10240775A1 (en) | 2002-08-30 | 2004-03-11 | Röhm GmbH & Co. KG | Process for removing metal ions from polymers or polymer solutions |
| DE10302096B4 (en) * | 2003-01-16 | 2005-03-17 | Coty B.V. | Cosmetic self-heating products and their use |
| EP1663090A4 (en) * | 2003-09-12 | 2010-07-21 | Z Medica Corp | Calcium zeolite hemostatic agent |
| DE602004030264D1 (en) * | 2003-09-12 | 2011-01-05 | Z Medica Corp | PARTLY HYDRATED HEMOSTATIC MEDIUM |
| JP4269073B2 (en) * | 2004-03-11 | 2009-05-27 | 岡井 洋 | Reactive hot melt curable composition and curing method |
| JP2005287913A (en) * | 2004-04-02 | 2005-10-20 | Suikoh Topline:Kk | Hybrid type mineral material for adsorption and removal of odorous component and hazardous component |
| DE102004026904A1 (en) * | 2004-06-01 | 2005-12-22 | Basf Ag | Highly functional, highly branched or hyperbranched polyesters and their preparation and use |
| JP2006008804A (en) * | 2004-06-24 | 2006-01-12 | Bridgestone Corp | Adhesive, method for producing the same and method for using the same and hose using the adhesive |
| JP2006008882A (en) * | 2004-06-28 | 2006-01-12 | Sanyo Chem Ind Ltd | Antistatic pressure-sensitive adhesive agent |
| EP1809122A1 (en) * | 2004-08-12 | 2007-07-25 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | A method for enzymatic cross-linking of a protein, cross-linked protein thus obtained and use thereof |
| EP1988938A4 (en) * | 2006-02-27 | 2011-09-28 | Agency Science Tech & Res | HARDENABLE BONE CEMENT |
-
2006
- 2006-02-09 DE DE102006006904A patent/DE102006006904A1/en not_active Withdrawn
-
2007
- 2007-02-02 WO PCT/DE2007/000192 patent/WO2007090373A2/en not_active Ceased
- 2007-02-02 ES ES15202504T patent/ES2771824T3/en active Active
- 2007-02-02 EP EP07702422.2A patent/EP1984032B1/en active Active
- 2007-02-02 EP EP15202504.5A patent/EP3050579B1/en active Active
- 2007-02-02 ES ES07702422.2T patent/ES2566054T3/en active Active
- 2007-02-09 US US12/223,772 patent/US7923003B2/en active Active
- 2007-02-09 DE DE502007006879T patent/DE502007006879D1/en active Active
- 2007-02-09 AU AU2007213923A patent/AU2007213923C1/en active Active
- 2007-02-09 EP EP07704469A patent/EP1981552B1/en not_active Not-in-force
- 2007-02-09 AT AT07704469T patent/ATE504317T1/en active
- 2007-02-09 JP JP2008553771A patent/JP2009525799A/en not_active Withdrawn
- 2007-02-09 JP JP2008553686A patent/JP2009525795A/en active Pending
- 2007-02-09 CN CN2007800051590A patent/CN101384284B/en active Active
- 2007-02-09 EP EP07721909A patent/EP1987111A2/en not_active Withdrawn
- 2007-02-09 CA CA2637794A patent/CA2637794C/en active Active
- 2007-02-09 CA CA2640771A patent/CA2640771C/en not_active Expired - Fee Related
- 2007-02-09 WO PCT/EP2007/001131 patent/WO2007090673A2/en not_active Ceased
- 2007-02-09 EP EP07711497.3A patent/EP1981553B1/en active Active
- 2007-02-09 US US12/223,899 patent/US20090280179A1/en not_active Abandoned
- 2007-02-09 WO PCT/DE2007/000241 patent/WO2007090384A2/en not_active Ceased
- 2007-02-09 CN CNA2007800047684A patent/CN101378789A/en active Pending
- 2007-02-09 WO PCT/EP2007/051251 patent/WO2007090880A2/en not_active Ceased
- 2007-02-09 AU AU2007213663A patent/AU2007213663A1/en not_active Abandoned
-
2011
- 2011-03-01 US US13/037,850 patent/US8440209B2/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5015677A (en) * | 1986-04-25 | 1991-05-14 | Bio-Polymers, Inc. | Adhesives derived from bioadhesive polyphenolic proteins |
| US20050283255A1 (en) * | 2001-06-04 | 2005-12-22 | Perry Geremakis | Tissue-derived mesh for orthopedic regeneration |
| US20050226904A1 (en) * | 2002-03-15 | 2005-10-13 | Hoon Choi | Fibrous composite for tissue engineering |
| US20040037906A1 (en) * | 2002-05-13 | 2004-02-26 | State Of Oregon Acting By And Through The Oregon State | Modified protein adhesives and lignocellulosic composites made from the adhesives |
Cited By (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE42208E1 (en) | 2003-04-29 | 2011-03-08 | Musculoskeletal Transplant Foundation | Glue for cartilage repair |
| USRE43258E1 (en) | 2003-04-29 | 2012-03-20 | Musculoskeletal Transplant Foundation | Glue for cartilage repair |
| US8221500B2 (en) | 2003-05-16 | 2012-07-17 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
| US7901457B2 (en) | 2003-05-16 | 2011-03-08 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
| US8292968B2 (en) | 2004-10-12 | 2012-10-23 | Musculoskeletal Transplant Foundation | Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles |
| US7815926B2 (en) | 2005-07-11 | 2010-10-19 | Musculoskeletal Transplant Foundation | Implant for articular cartilage repair |
| US9701940B2 (en) | 2005-09-19 | 2017-07-11 | Histogenics Corporation | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof |
| US20110027381A1 (en) * | 2006-10-16 | 2011-02-03 | Universitat Rostock | Treatment of osteoporosis |
| US8496971B2 (en) | 2006-10-16 | 2013-07-30 | Universitaet Rostock | Treatment of osteoporosis |
| US8906110B2 (en) | 2007-01-24 | 2014-12-09 | Musculoskeletal Transplant Foundation | Two piece cancellous construct for cartilage repair |
| US7837740B2 (en) | 2007-01-24 | 2010-11-23 | Musculoskeletal Transplant Foundation | Two piece cancellous construct for cartilage repair |
| US8435551B2 (en) | 2007-03-06 | 2013-05-07 | Musculoskeletal Transplant Foundation | Cancellous construct with support ring for repair of osteochondral defects |
| US20110040323A1 (en) * | 2007-08-03 | 2011-02-17 | Aesculap Ag | Combination for an adhesive bonding of biological tissues |
| US8460703B2 (en) | 2007-08-03 | 2013-06-11 | Aesculap Ag | Combination for an adhesive bonding of biological tissues |
| US20110182965A1 (en) * | 2010-01-26 | 2011-07-28 | Warsaw Orthopedic, Inc. | Highly compression resistant matrix with porous skeleton |
| US8758791B2 (en) | 2010-01-26 | 2014-06-24 | Warsaw Orthopedic, Inc. | Highly compression resistant matrix with porous skeleton |
| US20110243913A1 (en) * | 2010-04-06 | 2011-10-06 | Orthovita, Inc. | Biomaterial Compositions and Methods of Use |
| US10182973B2 (en) | 2010-11-10 | 2019-01-22 | Stryker European Holdings I, Llc | Polymeric bone foam composition and method |
| US11185475B2 (en) | 2010-11-10 | 2021-11-30 | Stryker European Operations Holdings Llc | Polymeric bone foam composition and method |
| EP2901968A1 (en) | 2011-06-23 | 2015-08-05 | Stryker Corporation | Prosthetic implant |
| WO2012178031A1 (en) | 2011-06-23 | 2012-12-27 | Stryker Corporation | Prosthetic implant and method of implantation |
| US12268609B2 (en) | 2013-03-07 | 2025-04-08 | Howmedica Osteonics Corp. | Method of manufacturing a tibial implant |
| US12343261B2 (en) | 2013-03-07 | 2025-07-01 | Howmedica Osteonics Corp. | Partially porous tibial component |
| US12279961B2 (en) | 2013-03-07 | 2025-04-22 | Howmedica Osteonics Corp. | Method of manufacturing a tibial implant |
| US9427334B2 (en) | 2013-03-08 | 2016-08-30 | Stryker Corporation | Bone pads |
| US9579216B2 (en) | 2013-03-08 | 2017-02-28 | Stryker Corporation | Bone pads |
| US9937059B2 (en) | 2013-03-08 | 2018-04-10 | Stryker Corporation | Bone pads |
| US10537441B2 (en) | 2013-03-08 | 2020-01-21 | Stryker Corporation | Bone pads |
| US11318027B2 (en) | 2013-03-08 | 2022-05-03 | Stryker Corporation | Bone pads |
| US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
| US11555172B2 (en) | 2014-12-02 | 2023-01-17 | Ocugen, Inc. | Cell and tissue culture container |
| US12076422B2 (en) | 2017-05-10 | 2024-09-03 | Marquette University | Medical and dental integrated multiphasic biomaterials for single or multi-tissue reconstruction/regeneration |
| AU2018266193B2 (en) * | 2017-05-10 | 2024-03-28 | Marquette University | Medical and dental integrated multiphasic biomaterials for single or multi-tissue reconstruction/regeneration |
| AU2018266193C1 (en) * | 2017-05-10 | 2025-05-29 | Marquette University | Medical and dental integrated multiphasic biomaterials for single or multi-tissue reconstruction/regeneration |
| WO2018209101A1 (en) * | 2017-05-10 | 2018-11-15 | Marquette University | Medical and dental integrated multiphasic biomaterials for single or multi-tissue reconstruction/regeneration |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090280179A1 (en) | Resorbable Calcium Phosphate Based Biopolymer-Cross-Linked Bone Replacement Material | |
| Hofman et al. | Bioinspired underwater adhesives by using the supramolecular toolbox | |
| Li et al. | Mineral-enhanced polyacrylic acid hydrogel as an oyster-inspired organic–inorganic hybrid adhesive | |
| Ahn | Perspectives on mussel-inspired wet adhesion | |
| Sánchez‐Fernández et al. | Bone‐adhesive materials: clinical requirements, mechanisms of action, and future perspective | |
| Mehdizadeh et al. | Design strategies and applications of tissue bioadhesives | |
| Lee et al. | Mussel-inspired adhesives and coatings | |
| Shao et al. | A water‐borne adhesive modeled after the sandcastle glue of P. californica | |
| US20070092483A1 (en) | Surgical adhesive compostion and process for enhanced tissue closure and healing | |
| CN105873594B (en) | Cross-linked material containing branched elastin | |
| EP1490122B1 (en) | Method for attaching two surfaces to each other using a bioadhesive polyphenolic protein and periodate ions. | |
| Xu et al. | An integrated asymmetric wet adhesive hydrogel with gradient charge distribution induced by electrostatic field | |
| US11389563B2 (en) | Dermal filler | |
| CN1341032A (en) | Medical adhesives | |
| Basak | Co-evolving with nature: the recent trends on the mussel-inspired polymers in medical adhesion | |
| Kong et al. | Synthetic polypeptide bioadhesive based on cation− π interaction and secondary structure | |
| Hollingshead et al. | Effect of cross-linkers on mussel-and elastin-inspired adhesives on physiological substrates | |
| Yuan et al. | Citrate-based mussel-inspired magnesium whitlockite composite adhesives augmented bone-to-tendon healing | |
| US20180193520A1 (en) | Injectable Polyurethanes and Applications Thereof | |
| JP2023521088A (en) | Xylitol-doped citrate composition and use thereof | |
| Shao et al. | Controlled curing of adhesive complex coacervates with reversible periodate carbohydrate complexes | |
| WO2004005421A1 (en) | Use of an acidic aqueous solution of a bioadhesive polyphenolic protein as an adhesive or coating | |
| EP1453553B1 (en) | Method and kit providing bioadhesive binding or coating with polyphenolic mussel proteins | |
| US20220306922A1 (en) | Adhesive composition and method of making and using the same | |
| Zhou et al. | Homogeneous “Hard‐Soft” Biphasic Bone Adhesives Promote Comminuted Fracture Healing through Interfacial Adaptation and Mechanical Property Maintenance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: DOT GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NEUMANN, HANS-GEORG;KLINKENBERG, ERNST-DIETER;SCHAUER, FRIEDER;AND OTHERS;REEL/FRAME:021909/0724;SIGNING DATES FROM 20080808 TO 20080825 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |